Analysts forecast that VIVUS, Inc. (NASDAQ:VVUS) will announce earnings of ($0.53) per share for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for VIVUS’s earnings. VIVUS reported earnings per share of ($1.00) in the same quarter last year, which suggests a positive year-over-year growth rate of 47%. The business is scheduled to announce its next quarterly earnings results on Tuesday, March 12th.
On average, analysts expect that VIVUS will report full year earnings of ($3.59) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($3.77) per share. Zacks’ EPS averages are a mean average based on a survey of research firms that cover VIVUS.
Get VIVUS alerts:
A number of analysts have weighed in on VVUS shares. ValuEngine raised shares of VIVUS from a “hold” rating to a “buy” rating in a report on Thursday, November 1st. Zacks Investment Research raised shares of VIVUS from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a report on Saturday, January 19th.
A number of institutional investors have recently modified their holdings of VVUS. Renaissance Technologies LLC boosted its holdings in VIVUS by 5.4% in the 2nd quarter. Renaissance Technologies LLC now owns 8,273,800 shares of the biopharmaceutical company’s stock valued at $5,833,000 after purchasing an additional 423,100 shares during the period. Worth Venture Partners LLC bought a new stake in VIVUS in the 3rd quarter valued at $132,000. Finally, Virtu Financial LLC bought a new stake in VIVUS in the 4th quarter valued at $29,000. 17.10% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ VVUS traded down $0.20 during trading hours on Thursday, hitting $5.05. 173,241 shares of the stock were exchanged, compared to its average volume of 256,389. VIVUS has a one year low of $2.15 and a one year high of $9.90. The company has a market cap of $55.91 million, a P/E ratio of -1.74 and a beta of 2.09.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Recommended Story: Do closed-end mutual funds pay dividends?
Get a free copy of the Zacks research report on VIVUS (VVUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com